bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A

8/23/18

Summary

bluebird bio is a clinical-stage biotechnology company focused on gene therapy, cancer immunopathy and gene editing for the treatment of cancer and rare diseases.

Its gene therapy pipeline is showing groundbreaking results, providing treatments for a variety of untreatable rare diseases, while its cancer immunopathy pipeline shows curative results in heavily pretreated patients.

I estimate recurring peak revenue of more than USD 600mn. and an opportunity for additional annual revenues of more than USD 670mn. - almost USD 1.3bn. in total.

Shares have come down from their March 2018 peak despite the absence of company-specific negative news but are bound to recover due to a number of catalysts until year-end.

Under consideration of recent transactions in the gene therapy/CAR-T space, bluebird could also warrant a substantial premium in an M&A scenario.

bluebird bio (BLUE) is a clinical-stage biotechnology company focused on gene therapy, cancer immunopathy and gene editing for the treatment of cancer and rare diseases. I believe that bluebird's therapies have the potential to be truly groundbreaking, not only offering symptom treatment, but sometimes even a cure to diseases that previously had no existing treatment or cure. However, despite a stream of positive clinical data and the absence of company-specific negative news, shares have come down from their March 2018 peak. Until year-end, the company is set to publish a stream of pipeline data, which should serve as a catalyst for the stock price. Based on recent acquisitions, it could also be an attractive buyout candidate.

READ FULL ARTICLE HERE